A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

X-linked Hypohidrotic Ectodermal Dysplasia

Interventions

DRUG

EDI200

Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.

Trial Locations (2)

Community Research, Cincinnati

University of California, San Francisco, San Francisco